Moreover, a recent study reported that a new selective CDK12/13 inhibitor (SR‐4835) also displayed synthetic lethality in combination with DNA‐damaging agents in triple negative breast cancer cells [140]. The gene discussed is CDK12; the disease is triple-negative breast carcinoma.